Rx-360 Receives Mixed Reviews on Sharing Audits

The drug industry is expressing some skepticism about relying on an Rx-360 Consortium plan to conduct and share supply-chain audits as the months-old consortium sets up working groups toward that end.

 

Rx-360 would choose suppliers for audits based on member input, and members could view audit results on a subscription basis from a database maintained by the consortium. The database will contain sensitive information, so suppliers must grant permission for each member that wants to view the audit results.

The industry may have a gut reaction against shared audits, Jackie Torfin, director of quality for Arizant Healthcare, said. “My guess is people will be slow to adopt until they see some of the bigger players take the lead,” she added.
Drug GMP Report